Health Care & Life Sciences » Pharmaceuticals | Proteomics International Laboratories Ltd.

Proteomics International Laboratories Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
-
1,149.20
1,328.50
916.50
1,440.10
Depreciation, Depletion & Amortization
-
2.40
2.70
165.20
235.70
Other Funds
-
-
96.00
-
-
Funds from Operations
-
438.50
1,111.80
902.60
1,132.70
Changes in Working Capital
-
238.70
397.50
568.30
48.80
Net Operating Cash Flow
-
677.30
1,509.30
1,470.90
1,083.90
Capital Expenditures
-
-
14.10
147.00
50.50
Net Investing Cash Flow
-
-
14.10
147.00
50.50
Issuance/Reduction of Debt, Net
-
25.00
-
75.50
-
Net Financing Cash Flow
-
2,646.30
100.70
1,810.70
2,676.00
Net Change in Cash
-
1,969.00
1,422.70
192.90
1,541.60
Free Cash Flow
-
677.30
1,523.40
1,617.80
1,134.40
Change in Capital Stock
-
2,621.30
4.60
1,886.20
3,276.90

About Proteomics International Laboratories

View Profile
Address
QEII Medical Centre
Perth Western Australia (WA) 6009
Australia
Employees -
Website http://www.proteomics.com.au
Updated 07/08/2019
Proteomics International Laboratories Ltd. is a biological research and drug discovery company. It operates through three synergistic business units: Analytical services, Diagnostics and Therapeutics. The Analytical services unit engages in contract research, analytical testing and consultancy.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.